BREAST PROTOCOLS

Breast In Situ

NSABP b-43:  A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Breast Neoadjuvant

ACOSOG Z1031:  A  Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III  Estrogen Receptor Positive Breast Cancer  (Cohort A closed, Cohort B open) Cooperative Trial (no credit)

Breast Adjuvant

ECOG pacct-1:  Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning Individualized Options for Treatment.  The TAILORx Trial.

SWOG S0221:  Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Pac given either every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.

ECOG E5103:  A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer Study.

NCCTG N063D/ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study. A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer 

Breast Advanced

SWOG S0622: Phase II studies of two different schedules of Dasatinib (NSC-732517) in bone metastasis predominant metastatic breast cancer

CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer (BREAST, PROSTATE, and MULTIPLE MYELOMA)(repeat)

HEAD AND NECK PROTOCOLS

RTOG  0436:  A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated without Surgery

INST OSI3602s: Multi-center Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy versus Cisplatin and Radiotherapy in Patient Stage III and IV Squamous Cell Carcinoma of the Head and Neck

ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer

INST OSI4641s: A Phase II Study of Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory or -Ineligible, Advanced, Squamous Cell Carcinoma of the Head and Neck

RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

LUNG PROTOCOLS

ECOG E1505:  A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC) 

Pharm H3E-US-S130: Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer of Nonsquamous Histology. (Eli Lilly)